Although third generation aromatase inhibitors exhibit certain advantages over tamoxifen in postmenopausal breast cancer patients, tamoxifen remains the first-line treatment for numerous ER-positive breast cancer patients. This evidence concerns the gene CYP19A1 and breast cancer.